Illegal Activity
none
Blackmail
none
Date
2018
Document Type
report
Model
gemini-2.0-flash-001
Processed
2026-02-07T18:43
Summary
This Deutsche Bank report analyzes AstraZeneca, recommending a 'BUY' rating. It highlights the company's strong pipeline, potential for EPS growth, and margin improvement, suggesting a positive outlook for the stock.
Metadata
- Subject
- AstraZeneca - Richard Parkes, BUY
- Sender
- Deutsche Bank Research
- Recipients
- —
- Document ID
- DB-SDNY-0086801, SDNY_GM_00232985
- Date
- 2018
Relationships 1
| Entity 1 | Relationship | Entity 2 | Description |
|---|---|---|---|
| Richard Parkes | Analyst | AstraZeneca | Richard Parkes is an analyst at Deutsche Bank covering AstraZeneca. |
Notable Quotes 2
2018 is a likely turning point for margin and EPS momentum.
Best-in-class pipeline. Exceptional data on new oncology portfolio puts AZ in a strong position despite MYSTIC failure.
Financial Information
Amounts:5171p5700p10%>$2bn7500p6500p5500p4500p3500p2500p1500p1083p228p513p5700p285p>$7bn
Public Knowledge
- Context
- This is an investment analysis report, which is typically shared with clients and may become public knowledge.
- Media Worthy
- Yes
Raw Analysis JSON
click to expand
Themes
Financial transactions/money flowBusiness dealings
People 1
Organizations 2
Deutsche BankAstraZeneca
Financial Entities 1
Deutsche Bank
Text Analysis
- Tone
- Professional
- Purpose
- To provide an analysis of AstraZeneca's stock and future prospects.
- Significance
- The document provides investment advice on AstraZeneca stock, highlighting potential growth and catalysts.
File Info
- File Name
- EFTA01385515.txt
- Dataset
- dataset_10
- Type
- Text
- Model
- gemini-2.0-flash-001
- Processed
- 2026-02-07T18:43:37.913785
- DOJ Source
- View on DOJ